ValTech Lifesciences GmbH
Prosthetic heart valves with reduced thrombogenicity.
The unmet clinical need is a non-thrombogenic, durable heart valve prosthesis. A large number of patients suffer from limited valve durability and the limitations of anticoagulation therapy, or from the risk of thromboembolic stroke. This is even more severe in developing or underdeveloped countries. The global market for heart valve prostheses was valued at USD 11 billion in 2021 and was estimated to reach USD 25 billion by 2030.
The team of ValTech Lifesciences are brining together state-of-the-art fluid mechanical and cardiovascular engineering research, bringing a next-generation valve design to solve the unmet clinical need. The co-founders are Dr. Shaokai Zheng and Prof. Dr. Dominik Obrist from the University of Bern.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
ValTech Lifesciences GmbH
Prosthetic heart valves with reduced thrombogenicity.
Website:
www.valtechlifesciences.com
Headquarter:
Bern
Foundation Date:
December 2025
Technology:
- Medtech
Sectors:
- Cardiovascular
- Medical devices
- Medtech
Support received
